An SI Board Since November 2004 |
Posts |
SubjectMarks |
Bans |
4 |
1 |
0
|
|
In September, Emisphere announced that it entered into a licensing agreement with Novartis Pharma AG to develop an oral formulation of recombinant human growth hormone (rhGH). Under the terms of the milestone- based agreement, Novartis may pay Emisphere up to $34 million during the course of product development, and a royalty increasing to double-digit rates based upon sales. Including the initial payment, Emisphere could achieve milestone-based payments of up to $6 million over the course of the next year.
The companies formed the agreement following successful completion of pre-clinical feasibility studies for rhGH with Emisphere's eligen(R) technology. Emisphere identified delivery agents that can deliver therapeutically sufficient levels of rhGH to the blood stream when administered orally. The lead carrier for rhGH has completed extensive formulation and preclinical safety studies.
A similar collaboration has been nade between Emisphere and Roch. Making it possilbe to switch from injecting meicine to absorging it through pills orally would be a great accivment.
|
|